Pablo Tolosa
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2026
Performance Evaluation of a Novel Non-Invasive Monitoring Device for At-Home Neutropenia Detection in a Multicenter Cancer Cohort.
Journal: American journal of hematology
Published: April 07, 2026
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.
Journal: International journal of molecular sciences
Published: March 27, 2026
Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.
Journal: Therapeutic advances in medical oncology
Published: January 27, 2026
Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.
Journal: Breast cancer research and treatment
Published: December 22, 2025
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
Journal: Breast cancer research and treatment
Published: November 04, 2025
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.
Journal: Cancer treatment reviews
Published: October 05, 2025
Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2- breast cancer.
Journal: Med (New York, N.Y.)
Published: July 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.
Journal: ESMO open
Published: June 05, 2025
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: October 29, 2024
Last Updated: 09/26/2026